Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment - Takeaways - MDSpire

Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

  • By

  • Ee Wen Loh

  • Miguel Debono

  • June 30, 2026

  • 0 min

Share

  • 1

    Mild autonomous cortisol secretion (MACS) is characterized by elevated cortisol levels without overt Cushing’s syndrome symptoms.

  • 2

    Surgical intervention, such as adrenalectomy, may improve metabolic outcomes in MACS patients with multiple comorbidities.

  • 3

    Metyrapone has shown promise in lowering nocturnal cortisol levels and improving metabolic risk parameters in MACS patients.

  • 4

    Mifepristone treatment has led to significant reductions in insulin resistance and HbA1c levels in patients with MACS.

  • 5

    Evidence for the efficacy of medical therapies in MACS remains inconsistent, highlighting the need for further research.

Original Source(s)

Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment

  • by Ee Wen Loh, Miguel Debono

  • June 30, 2026

Related Content

Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study

Metabolic Health Tied to Dementia

In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.